Bloated on arrival? Biotech's weightiest new issues
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Years of dreams about CARs turn into reality for Atara
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.
Biopharma's record venture year ends with a slowdown
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Death of a unicorn
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Ash 2018 – Legend’s mystery CAR raises more questions
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
